Tools
Appendiceal Tumors
Introduction
Appendiceal tumors constitute a rare and heterogeneous group of neoplasms with variable malignant potential. The age-adjusted annual incidence is approximately 0.5 to 1 per 100,000 population. These lesions are identified in 0.9% to 1.4% of appendectomy specimens, representing a small fraction of the more than 300,000 appendectomies performed annually in the U.S.[1][2][3]
Clinical manifestations are typically nonspecific and often mimic acute appendicitis. Consequently, most diagnoses are made incidentally during surgery or histopathologic examination of the resected specimen. These tumors have an indolent course and lack distinctive symptoms, and many cases present at locally advanced or metastatic stages.[4]
Histopathologic subtypes include epithelial neoplasms—such as mucinous neoplasms, adenocarcinomas, and goblet cell tumors—as well as neuroendocrine tumors (NETs). Management involves a multimodal approach incorporating surgical resection, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) when indicated, systemic chemotherapy, and targeted immunotherapy.[5] Prognosis is determined by histologic subtype, tumor grade, disease stage, and completeness of cytoreduction, underscoring the importance of accurate classification and individualized treatment planning.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
The etiology of appendiceal tumors is heterogeneous and varies according to histologic subtype. The pathogenesis is incompletely elucidated for several tumor types, with both genetic and environmental factors contributing to neoplastic transformation.
Genetic and Molecular Factors
Mucinous neoplasms of the appendix are believed to arise through molecular pathways similar to those implicated in colorectal adenocarcinomas. Two principal mechanisms have been identified: the chromosomal instability pathway and the microsatellite instability pathway.
The chromosomal instability pathway involves the stepwise accumulation of genetic alterations, including activating point mutations in the KRAS proto-oncogene, inactivating mutations in the TP53 tumor suppressor gene on chromosome 17p, loss of APC gene function on chromosome 5q, and aberrations in the β-catenin signaling pathway. The microsatellite instability pathway results from defects in DNA mismatch repair genes such as MSH2, MLH1, PMS2, PMS1, and GTBP, leading to genomic instability and accelerated tumorigenesis.[6]
NETs and goblet cell adenocarcinomas (GCAs) arise through distinct and incompletely characterized molecular mechanisms that differ from those of epithelial mucinous neoplasms. Current evidence suggests possible roles for unique genetic alterations and cellular origins, although the etiopathogenesis is under investigation.[7]
Medical Risk Factors
Chronic inflammatory bowel disease, including ulcerative colitis and Crohn disease, constitutes an established risk factor for appendiceal mucinous neoplasms.[8] The duration and severity of intestinal inflammation correlate with increased risk of malignant transformation, although the absolute risk elevation is modest. Most appendiceal tumors occur sporadically without identifiable hereditary syndromes or familial clustering. However, genetic evaluation should be considered in patients with confirmed appendiceal malignancy, particularly when associated with other colorectal or extracolonic cancers.[9]
Epidemiology
A gradual increase in the incidence of appendiceal tumors has been reported, with neoplasms identified in approximately 0.9% to 1.4% of appendectomy specimens.[10][11][12] NETs are the most common subtype, with an annual incidence of 0.15 to 0.6 per 100,000 population. These tumors demonstrate a female predominance and typically affect younger individuals.[13]
Epithelial tumors of the appendix comprise only 0.1% of all epithelial malignancies of the colon and rectum but represent the most frequent malignant neoplasms of the appendix.[14] This group includes mucinous appendiceal neoplasms with variable malignant potential, nonmucinous or colonic-type adenocarcinomas, and GCAs.[15] These epithelial neoplasms are generally diagnosed in the 7th decade of life and exhibit a slight female predominance.[16]
Signet ring cell carcinoma, an aggressive variant of mucinous adenocarcinoma, accounts for approximately 4% of appendiceal malignancies.[17] GCA is another rare and aggressive tumor, with a reported incidence of 0.05 to 0.3 per 100,000 population, most frequently observed in the 7th decade of life.[18]
Primary appendiceal lymphomas, primarily Burkitt lymphoma and diffuse large B-cell lymphoma, occur more commonly in young male persons (1.5:1) and have a mean age at diagnosis of approximately 18 years.[19]
Pathophysiology
The appendix exhibits the same layered wall architecture as the colon but contains abundant gut-associated lymphoid tissue within the submucosa and a high concentration of goblet cells within the mucosal epithelium. Since the appendix possesses a single luminal connection to the cecum, obstruction of the appendiceal orifice by tumor cells or intraluminal mucin may result in luminal distention, venous congestion, and secondary bacterial infection. This pathophysiologic process accounts for the observation that more than half of patients with appendiceal tumors initially present with clinical manifestations consistent with acute appendicitis.[20]
In mucinous appendiceal neoplasms, progressive accumulation of mucin leads to cystic dilatation of the appendix, termed an "appendiceal mucocele." Rupture of the distended appendix allows dissemination of mucin and neoplastic epithelial cells throughout the peritoneal cavity, producing mucinous peritoneal deposits and resulting in pseudomyxoma peritonei (PMP) or, in advanced stages, peritoneal carcinomatosis. The extent of peritoneal dissemination closely correlates with tumor grade and the completeness of cytoreduction achieved during surgical intervention.[21]
Histopathology
Appendiceal tumors are classified into 5 principal histologic subtypes. Epithelial tumors include mucinous neoplasms, GCAs, colonic-type (nonmucinous) adenocarcinomas, and signet ring cell adenocarcinomas. Nonepithelial tumors primarily consist of neuroendocrine neoplasms. Less common entities include lymphoma, mesenchymal tumors such as gastrointestinal stromal tumors, desmoid tumors, leiomyomas, and leiomyosarcomas. Neuroectodermal tumors and nerve sheath tumors, including schwannoma and neurofibroma, as well as metastatic deposits, are also observed within this anatomic site.[22]
The mucinous category comprises a heterogeneous group ranging from simple adenomas to invasive adenocarcinomas and PMP.[23] Classification is based on histologic grade and extent of invasion. Mucinous adenomas and low-grade appendiceal mucinous neoplasms (LAMN) are confined to the appendiceal mucosa, whereas high-grade mucinous adenocarcinomas exhibit invasion beyond the muscularis mucosa. Signet ring cell carcinoma constitutes a rare but highly aggressive variant of mucinous adenocarcinoma characterized by mucin-laden malignant cells dispersed within pools of extracellular mucin. Owing to its aggressive biological behavior, distant metastases are present in up to 60% of cases at the time of diagnosis.[24]
PMP is characterized by intraperitoneal dissemination of extracellular mucin secreted by mucin-producing epithelial tumors of the appendix. Histologically, mucinous implants consist of amorphous pools of mucin admixed with fibrous stroma and noninvasive mucin-secreting epithelium. Immunohistochemically, the hallmark finding is cytokeratin 20 positivity, with occasional coexpression of cytokeratin 7.[25]
Nonmucinous adenomatous tumors include colonic-type adenocarcinoma of the appendix. These neoplasms share similar etiopathogenic mechanisms, histologic architecture, and staging parameters with primary colorectal adenocarcinomas. Microscopic examination reveals malignant glandular formations with architectural distortion, nuclear stratification, and loss of normal mucosal organization.[26]
NETs of the appendix are most frequently located at the appendiceal tip, are typically well-differentiated, and exhibit a relatively indolent clinical course. Microscopically, these tumors consist of uniform submucosal cell clusters arranged in nested or insular patterns, with nuclei demonstrating the characteristic “salt and pepper” chromatin typical of neuroendocrine differentiation. Chromogranin A serves as a valuable biomarker for assessing treatment response and detecting disease recurrence.[27] According to the World Health Organization (WHO) classification, appendiceal neuroendocrine neoplasms are categorized as well-differentiated NETs, poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs).
GCAs display combined features of neuroendocrine and epithelial differentiation and are, therefore, referred to as "mucinous adenoneuroendocrine carcinomas."[28] Other uncommon appendiceal tumors include lymphomas and sarcomas, which arise from the submucosa due to the organ’s abundant lymphoid tissue and exhibit histologic features similar to those of their counterparts in other gastrointestinal locations.
History and Physical
The clinical presentation of appendiceal tumors is typically nonspecific, with more than 50% of patients remaining asymptomatic at diagnosis.[29] When symptoms occur, their nature and severity vary according to the histologic type of neoplasm. Progressive intraluminal accumulation of mucin in mucinous appendiceal neoplasms leads to appendiceal distention and the formation of a mucocele, irrespective of tumor grade. This process may manifest as vague abdominal discomfort or a palpable mass in the right iliac fossa.
In the early stages, the most frequent clinical manifestation resembles acute appendicitis, characterized by acute right lower quadrant (RLQ) pain accompanied by anorexia, nausea, and vomiting.[30] Although these features often mimic acute appendicitis, certain clinical factors should raise suspicion for underlying appendiceal malignancy. These factors include advanced age, atypical or recurrent abdominal pain, unexplained anemia, weight loss, inflammatory bowel disease, or a family history of Lynch syndrome-associated cancers.[31]
In advanced stages of appendiceal mucinous neoplasms, progression to PMP results in progressive abdominal distension due to the accumulation of mucin within the peritoneal cavity. Associated manifestations may include chronic abdominal pain, anemia, weight loss, infertility, and the development of new-onset ventral hernias.[32][33] Intestinal obstruction is uncommon in PMP despite extensive mucinous deposition, in contrast to peritoneal carcinomatosis arising from colonic-type adenocarcinoma.[34][35]
Appendiceal NETs are frequently asymptomatic and are most often identified incidentally during appendectomy or histopathologic examination. Carcinoid syndrome secondary to hepatic metastases from appendiceal NETs occurs in fewer than 5% of cases.
Physical examination may reveal RLQ tenderness with guarding, a palpable abdominal mass, ascites, or signs of metastatic spread. Patients with gastroenteropancreatic NETs complicated by hepatic metastases may exhibit features of carcinoid syndrome, including flushing, diarrhea, and postural hypotension.[36]
Evaluation
The diagnostic evaluation of appendiceal tumors is guided by clinical presentation and underlying histologic subtype. Timely and accurate diagnosis is critical to prevent treatment delays and ensure complete surgical resection.
Imaging Studies
Ultrasound is often the initial imaging modality, particularly in patients presenting with RLQ pain. Sonographic findings suggestive of appendiceal neoplasm include a cystic or tubular structure with lamellated “onion-skin” internal echoes characteristic of mucinous lesions. Although useful in detecting mucoceles and appendiceal masses, ultrasound provides limited information for precise tumor characterization and staging.[37][38]
Contrast-enhanced computed tomography (CT) is the preferred imaging technique for suspected appendiceal neoplasms. Typical findings may include an enlarged appendix (>15 mm), mural irregularity, or a soft-tissue mass. CT reliably evaluates local invasion, lymphadenopathy, and peritoneal dissemination. Rim calcification of mucinous nodules and scalloping of hepatic margins are classic features of PMP.[39][40]
Magnetic resonance imaging (MRI) is indicated when detailed soft-tissue characterization is required or CT contrast is contraindicated. MRI offers superior visualization of mucinous content and peritoneal spread, particularly on T2-weighted sequences.[41]
The use of positron emission tomography (PET) with somatostatin receptor tracers is recommended for NETs larger than 2 cm, particularly in the presence of positive margins or nodal metastases. PET/CT or PET/MRI aids in identifying occult metastases and determining the need for additional surgical intervention.[42]
Chest CT is recommended for all patients following histologic confirmation. This evaluation is essential to exclude pulmonary metastases, irrespective of tumor subtype.
Imaging characteristics vary by histologic subtype and provide valuable information for diagnosis and staging. Mucinous epithelial neoplasms typically demonstrate appendiceal dilatation consistent with a mucocele, periappendiceal or peritoneal mucin accumulation, scalloping of hepatic margins, and calcified deposits. Colonic-type adenocarcinomas present as irregular appendiceal wall thickening with periappendiceal fat stranding, nodal enlargement, and evidence of visceral metastases. NETs appear as small, enhancing masses at the appendiceal tip, occasionally accompanied by regional lymphadenopathy or hepatic metastases. Primary lymphomas exhibit diffuse mural thickening with aneurysmal dilatation and luminal expansion.
Endoscopic Evaluation
Colonoscopy is a critical preoperative investigation for all confirmed epithelial appendiceal neoplasms to exclude synchronous colonic lesions. Typical colonoscopic findings include a bulging appendiceal orifice with associated ulceration or mucosal irregularity. Endoscopic ultrasound provides additional information regarding mural invasion and regional nodal involvement. However, colonoscopy is contraindicated in the setting of acute appendicitis and may fail to detect tumors located in the distal appendix, including NETs.[43]
Laboratory and Tumor Markers
Serum tumor markers assist in prognostication and postoperative surveillance of appendiceal neoplasms. Carcinoembryonic antigen, cancer antigen 19-9, and cancer antigen 125 are particularly useful for mucinous tumors and PMP, with elevated carcinoembryonic antigen levels correlating with advanced disease and reduced progression-free survival following CRS-HIPEC.[44] Chromogranin A serves as the principal biomarker for NETs, with serial measurements aiding in the detection of recurrence or metastatic progression.[45]
Treatment / Management
The management of appendiceal tumors is determined by histologic subtype, tumor grade, and disease extent. Surgical resection remains the cornerstone of curative treatment, complemented by systemic or regional chemotherapy in advanced or high-grade cases (see below).
Differential Diagnosis
With the growing interest in nonoperative management of acute appendicitis, distinguishing benign inflammatory causes from appendiceal tumors has become increasingly important.[46] An appendicular mass may be a sequela of acute appendicitis or a lesion misdiagnosed as lymphangioma, mesenteric cyst, retroperitoneal tumor, ovarian cyst, or ovarian neoplasm.[47] Appendiceal neoplasms must be excluded in patients with clinical red flags, such as advanced age, altered bowel habits, unexplained weight loss, inflammatory bowel disease, or a family history of colorectal or Lynch-associated cancers.
The differential diagnosis of appendiceal tumors varies by histologic subtype. Differentiation between PMP, which is associated with appendiceal mucinous neoplasms, and peritoneal carcinomatosis, typically arising from primary colorectal, ovarian, or pancreatic malignancies, is essential for appropriate management.
Surgical Oncology
Surgery is the primary treatment for localized appendiceal tumors, excluding primary lymphomas and unresectable metastatic disease. The extent of resection is guided by tumor type, histologic grade, and anatomical spread.
For Grade 1 appendiceal mucinous neoplasms (LAMN), laparoscopic appendectomy with clear margins is sufficient when no perforation or peritoneal disease is present. Comprehensive inspection of the peritoneal cavity—including paracolic gutters, pelvis, and subdiaphragmatic surfaces—is essential, and the mesoappendix should be included for accurate staging. Grade 2 to 3 appendiceal mucinous neoplasms require right hemicolectomy with oncologic lymphadenectomy. Open, laparoscopic, or robotic approaches are appropriate if oncologic principles are preserved.
CRS-HIPEC constitutes the standard of care for PMP. The procedure involves peritonectomy, omentectomy, and resection of involved organs such as the colon, gallbladder, distal stomach, spleen, and liver capsule, aiming for complete (CC-0) or near-complete (CC-1) cytoreduction. HIPEC is performed with mitomycin C or oxaliplatin at 41°C to 43 °C for 30 to 90 minutes using a perfusion circuit to ensure uniform drug distribution.[48][49]
For NETs, treatment is determined by tumor size, grade, and extent. Well-differentiated NETs measuring less than 2 cm are managed with appendectomy, provided margins are clear and no mesoappendiceal or lymphovascular invasion is evident. Tumors measuring 2 cm or greater, involving the appendiceal base, demonstrating high-grade NET features, or exhibiting mixed NEC morphology require right hemicolectomy to achieve complete resection and nodal clearance.[50]
In GCA, appendectomy is curative for lesions less than 1 cm in size and confined to the appendix. Tumors measuring greater than 1 cm or extending beyond the appendix necessitate right hemicolectomy for adequate oncologic resection. Patients with carcinomatosis and a peritoneal cancer index (PCI) less than 18 may undergo CRS-HIPEC at high-volume centers following interprofessional evaluation.[51]
For nonmucinous epithelial neoplasms, right hemicolectomy is indicated in the absence of peritoneal metastases. When peritoneal dissemination is present, CRS-HIPEC may be considered if complete cytoreduction is achievable.
Extent of Surgical Resection
The adequacy of appendectomy alone is controversial, particularly for incidentally discovered tumors. According to the National Comprehensive Cancer Network's guidelines, appendectomy alone is appropriate for T1 low-grade adenocarcinomas without lymphovascular invasion. However, most invasive adenocarcinomas require right hemicolectomy to ensure accurate staging and margin clearance.
Second-look diagnostic laparoscopy is not routinely recommended unless increasing tumor marker levels indicate possible recurrence in the absence of radiologic evidence. Patients with extensive peritoneal carcinomatosis may be considered for CRS-HIPEC at specialized centers following interprofessional evaluation and systemic therapy. The PCI and completeness of cytoreduction (CC) score should be documented for prognostic assessment.[52]
Contraindications for CRS-HIPEC include the following:
- PCI greater than 12 in appendiceal adenocarcinoma
- Diffuse involvement of the small bowel serosa or mesentery
- Multiple small bowel obstructions
- Extensive retroperitoneal disease
- Tumor involvement of the porta hepatis or gastrohepatic ligament
- Biliary obstruction or hepatic parenchymal involvement necessitating a major hepatectomy
Optimal surgical strategy depends on precise histologic classification and the distribution of disease within the peritoneal cavity. Accurate assessment using PCI and CC scoring informs eligibility for CRS-HIPEC and overall prognosis.
Role of Hyperthermic Intraperitoneal Chemotherapy in Appendiceal Tumors
The Partenariat de Recherche en Oncologie Digestive (PRODIGE 7) trial demonstrated no survival benefit from adding HIPEC to CRS in colorectal carcinomatosis, although the study's methodology has been subject to debate.[53] Current consensus supports CRS-HIPEC for PMP and peritoneal carcinomatosis of appendiceal origin when complete cytoreduction is achievable and the PCI is favorable.[54] Completeness of cytoreduction, rather than HIPEC alone, is the most significant predictor of survival outcomes. CRS-HIPEC is addressed in detail in a separate StatPearls article.
Medical Oncology
Systemic therapy constitutes a critical component of interprofessional management for appendiceal tumors. Although dedicated treatment guidelines are lacking, most recommendations follow established protocols for colorectal cancer, with regimen selection and timing determined by histologic subtype, tumor grade, and disease stage.[55]
For appendiceal adenocarcinoma, GCA, and grade 2 or 3 mucinous adenocarcinoma, systemic chemotherapy using fluoropyrimidine- and oxaliplatin-based regimens (eg, folinic acid with fluorouracil and oxaliplatin, also known as FOLFOX; capecitabine with oxaliplatin, also known as CAPOX) is indicated in the neoadjuvant or adjuvant setting, depending on resectability and nodal involvement. In unresectable or recurrent disease, irinotecan-based regimens such as the FOLFIRI (folinic acid with fluorouracil and irinotecan) combination or targeted agents may be employed for palliative purposes. Systemic therapy may also be administered in conjunction with CRS-HIPEC to control micrometastatic disease and improve long-term outcomes.
In appendiceal NETs, systemic therapy is guided by tumor grade and biological behavior. Somatostatin analogues, including octreotide, lanreotide, and Lu-DOTATATE, provide symptom control and tumor suppression in well-differentiated NETs.[56] The RADIANT-2 trial (Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome) demonstrated improved progression-free survival with everolimus in advanced NETs and carcinoid syndrome, supporting the drug's role in systemic management.[57] Selected patients with progressive or metastatic disease may receive combination therapy with somatostatin analogues and targeted agents, while high-grade or poorly differentiated NETs may be treated with platinum- or temozolomide-based chemotherapy.[58]
Staging
Accurate classification of appendiceal tumors guides clinical management and research reporting. The tables below summarize standardized staging and grading systems for appendiceal neoplasms.
Peritoneal Surface Oncology Group International Staging of Appendiceal Mucinous Neoplasms
The Peritoneal Surface Oncology Group International (PSOGI) staging offers a structured approach to classify mucinous neoplasms of the appendix. The classification is based on histologic grade and the presence of cellular infiltration or PMP.
| Stage | Features |
| LAMN | Dysplastic lesion with low-grade cytohistologic features; no infiltration by neoplastic cells |
| High-grade AMN | Presence of high-grade cytohistologic features |
| Mucinous adenocarcinoma | Infiltration by neoplastic cells. Also termed by the AJCC as "grade 2" (moderately differentiated) and "grade 3" (poorly differentiated with or without signet ring cells) |
| PMP | Grade 1: Low-grade histologic features |
| Grade 2: High-grade histologic features | |
| Grade 3: Presence of signet ring cells [59] |
* AJCC: American Joint Committee on Cancer
American Joint Committee on Cancer Staging of Epithelial Tumours of the Appendix
The AJCC TNM classification provides a standardized framework for assessing appendiceal epithelial tumors. Tumors are staged according to depth of invasion (T), regional lymph node involvement (N), distant metastasis (M), and histologic differentiation (G).
Classification by depth of invasion
| T | Description |
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ |
| T1 | Tumor invades submucosa |
| T2 | Tumor invades muscularis propria |
| T3 | Tumor invades through muscularis propria into the subserosa or the mesoappendix |
| T4a | Tumor invades through the visceral peritoneum |
| T4b | Tumor directly invades other organs |
Classification based on the degree of regional lymph node involvement
| N | Description |
| N1 | 1-3 regional lymph nodes are positive |
| N1a: 1 node positive | |
| N1b: 2 or 3 nodes positive | |
| N1c: No positive regional nodes, but tumor deposits are present over the subserosa or mesentery | |
| N2 | 4 or more regional nodes are positive |
Classification based on the extent of distant metastasis
| M | Description |
| M1a | Intraperitoneal acellular mucin without identifiable tumor cells |
| M1b | Intraperitoneal metastasis of mucin with tumor cells |
| M1c | Metastasis to sites other than peritoneum |
Classification by histologic differentiation
| G | Description |
| G1 | Well differentiated |
| G2 | Moderately differentiated |
| G3 | Poorly differentiated |
World Health Organization Classification and Grading Criteria for Appendicular Neuroendocrine Tumors
The table below summarizes the WHO classification of appendiceal NETs based on tumor differentiation, mitotic rate, Ki-67 index, and overall grade. This framework includes poorly differentiated NEC and MiNEN.
| Stage | Differentiation | Grade | Mitotic Rate | Ki-67 Index |
| G1 | Well differentiated | Low | <2 | <3 |
| G2 | Well differentiated | Intermediate | 2-20 | 3-20 |
| G3 | Well differentiated | High | >20 | >20 |
| NEC | Poorly differentiated | High | >20 | >20 |
| MiNEN | Well or poorly differentiated | Variable | Variable | Variable |
Prognosis
Five-year survival rates for appendiceal tumors range from 27% to 93%. Prognosis depends on histologic type, tumor grade, advanced stage, spread of mucin beyond the RLQ, and presence of cellular mucin. Epithelial neoplasms are less aggressive than their colorectal counterparts, exhibiting less frequent regional lymphadenopathy and distant metastasis at diagnosis.[60] However, mucinous and signet ring cell histologies are associated with markedly reduced 5-year survival in appendiceal adenocarcinoma.[61] Patients with PMP who undergo CRS-HIPEC achieve overall 5- and 10-year survival rates of 72% and 54%, respectively, contingent upon the completeness of cytoreduction and histologic subtype.[62] Peritoneal carcinomatosis secondary to mucinous appendicular adenocarcinoma carries a poor prognosis, with 5-year survival below 10%.
Appendicular NETs confer the most favorable prognosis, with subcentimetric tumors demonstrating nearly 100% 5-year survival. Tumor size significantly impacts outcomes, with 5-year survival declining to just over 30% for lesions larger than 2 cm.[63][64] GCAs frequently progress to peritoneal carcinomatosis requiring CRS-HIPEC. Prognosis correlates with grade, as grade 1 tumors allow higher rates of complete cytoreduction and improved survival compared to grade 3. Longitudinal data are limited, with reported 5-year survival rates ranging from 23% to 54%.[65]
Complications
As mentioned, appendiceal tumors frequently present as acute appendicitis or an appendicular mass. Infective complications secondary to perforation, including localized or generalized peritonitis, can delay definitive management and contribute to disease progression. Mucinous ascites associated with PMP exerts pressure effects, leading to ventral hernias, chronic abdominal pain, anemia, weight loss, and anorexia. Recurrence is common despite CRS-HIPEC.[66] Mucinous adenocarcinomas with peritoneal carcinomatosis may result in small bowel, biliary, or ureteric obstruction due to tumor invasion.[67]
Appendiceal NETs measuring more than 2 cm or arising at the appendiceal base may also cause obstruction.[68] Carcinoid syndrome occurs in less than 1% of cases, typically in patients with hepatic metastases.[69] Mesenteric fibrosis, as seen in other gastroenteropancreatic NETs, can contribute to small bowel obstruction.
Treatment-related complications are substantial, particularly with CRS-HIPEC, where mortality and morbidity may reach 18% and 70%, respectively. Reported adverse events include small bowel perforation, anastomotic leaks, intra-abdominal abscesses, biliopancreatic fistulae, prolonged ileus, and pulmonary complications such as pneumonia and pleural effusion.[70] Systemic chemotherapy in neoadjuvant or adjuvant settings carries an overall toxicity rate up to 46%, most commonly gastrointestinal complications, followed by neuropathy and neutropenia.[71]
Deterrence and Patient Education
Although rare, appendiceal tumors most commonly present with clinical features of acute appendicitis. Identifying patients with occult malignancies is critical in the context of nonoperative management of acute appendicitis. Patient education is equally important as healthcare professional awareness in achieving early detection. Atypical symptoms and high-risk features, including advanced age, altered bowel habits, rectal bleeding, unexplained anemia, weight loss, and chronic abdominal discomfort, should be recognized as red flags. Rigorous histopathologic evaluation of appendectomy specimens is essential, as approximately 50% of appendiceal tumors are identified incidentally.
Enhancing Healthcare Team Outcomes
Optimal management of appendiceal tumors relies on coordinated interprofessional collaboration to ensure comprehensive, patient-centered care. Clinicians must maintain a high index of suspicion in patients presenting with atypical appendicitis or features suggestive of malignancy. Given that diagnosis is frequently retrospective, results should be communicated with sensitivity, and prompt access to counseling and support services must be provided.
Effective management requires input from surgical and medical oncologists, radiologists, oncopathologists, stoma therapists, nurses, pharmacists, physiotherapists, nutritionists, and palliative care specialists. Team-based discussions guide individualized treatment planning and ensure adherence to evidence-based protocols. Prehabilitation is recommended for patients undergoing extensive procedures, such as CRS-HIPEC, to optimize nutritional, physical, and psychological readiness.
Care coordination throughout diagnosis, treatment, and follow-up is essential to minimize delays, reduce complications, and maintain continuity. Regular interprofessional meetings, standardized communication pathways, and shared decision-making enhance safety and treatment consistency. Through structured collaboration and clear delineation of responsibilities, interprofessional teams can improve outcomes, quality of life, and the efficiency of patient-centered care for individuals with appendiceal tumors.
References
Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Annals of surgical oncology. 2012 May:19(5):1379-85. doi: 10.1245/s10434-012-2238-1. Epub [PubMed PMID: 22302267]
Marmor S, Portschy PR, Tuttle TM, Virnig BA. The rise in appendiceal cancer incidence: 2000-2009. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2015 Apr:19(4):743-50. doi: 10.1007/s11605-014-2726-7. Epub 2015 Jan 6 [PubMed PMID: 25560182]
Level 2 (mid-level) evidenceMcGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Diseases of the colon and rectum. 2005 Dec:48(12):2264-71 [PubMed PMID: 16258711]
Level 2 (mid-level) evidenceEchevarria S, Rauf F, Hussain N, Zaka H, Farwa UE, Ahsan N, Broomfield A, Akbar A, Khawaja UA. Typical and Atypical Presentations of Appendicitis and Their Implications for Diagnosis and Treatment: A Literature Review. Cureus. 2023 Apr:15(4):e37024. doi: 10.7759/cureus.37024. Epub 2023 Apr 2 [PubMed PMID: 37143626]
Kelly KJ. Management of Appendix Cancer. Clinics in colon and rectal surgery. 2015 Dec:28(4):247-55. doi: 10.1055/s-0035-1564433. Epub [PubMed PMID: 26648795]
Constantin M, Mătanie C, Petrescu L, Bolocan A, Andronic O, Bleotu C, Mitache MM, Tudorache S, Vrancianu CO. Landscape of Genetic Mutations in Appendiceal Cancers. Cancers. 2023 Jul 12:15(14):. doi: 10.3390/cancers15143591. Epub 2023 Jul 12 [PubMed PMID: 37509254]
Du Y, Ter-Minassian M, Brais L, Brooks N, Waldron A, Chan JA, Lin X, Kraft P, Christiani DC, Kulke MH. Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocrine-related cancer. 2016 Aug:23(8):587-94. doi: 10.1530/ERC-16-0171. Epub [PubMed PMID: 27492634]
Bonomi AM, Ferrario L, Frontali A, Danelli P, Colombo F. Appendiceal Mucinous Neoplasms and Inflammatory Bowel Disease: Systematic Review of the Literature. Journal of clinical medicine. 2023 Dec 29:13(1):. doi: 10.3390/jcm13010191. Epub 2023 Dec 29 [PubMed PMID: 38202199]
Level 1 (high-level) evidenceHolowatyj AN, Washington MK, Tavtigian SV, Eng C, Horton C. Inherited Cancer Susceptibility Gene Sequence Variations Among Patients With Appendix Cancer. JAMA oncology. 2022 Nov 11:9(1):95-101. doi: 10.1001/jamaoncol.2022.5425. Epub 2022 Nov 11 [PubMed PMID: 36368039]
Orchard P, Preece R, Thomas MG, Dixon SW, Wong NACS, Chambers AC, Messenger DE. Demographic trends in the incidence of malignant appendiceal tumours in England between 1995 and 2016: Population-based analysis. BJS open. 2022 Jul 7:6(4):. doi: 10.1093/bjsopen/zrac103. Epub [PubMed PMID: 36029031]
Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Annals of surgery. 2013 Jun:257(6):1072-8. doi: 10.1097/SLA.0b013e318269d680. Epub [PubMed PMID: 23001080]
Whitfield CG, Amin SN, Garner JP. Surgical management of primary appendiceal malignancy. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2012 Dec:14(12):1507-11. doi: 10.1111/j.1463-1318.2012.03052.x. Epub [PubMed PMID: 22515312]
Andrini E, Lamberti G, Alberici L, Ricci C, Campana D. An Update on Appendiceal Neuroendocrine Tumors. Current treatment options in oncology. 2023 Jul:24(7):742-756. doi: 10.1007/s11864-023-01093-0. Epub 2023 May 4 [PubMed PMID: 37140773]
Hatch QM, Gilbert EW. Appendiceal Neoplasms. Clinics in colon and rectal surgery. 2018 Sep:31(5):278-287. doi: 10.1055/s-0038-1642051. Epub 2018 Sep 4 [PubMed PMID: 30186049]
Aleter A, El Ansari W, Toffaha A, Ammar A, Shahid F, Abdelaal A. Epidemiology, histopathology, clinical outcomes and survival of 50 cases of appendiceal mucinous neoplasms: Retrospective cross-sectional single academic tertiary care hospital experience. Annals of medicine and surgery (2012). 2021 Apr:64():102199. doi: 10.1016/j.amsu.2021.102199. Epub 2021 Mar 6 [PubMed PMID: 33815784]
Level 2 (mid-level) evidenceMcCusker ME, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer. 2002 Jun 15:94(12):3307-12 [PubMed PMID: 12115365]
Sugarbaker PH. Epithelial appendiceal neoplasms. Cancer journal (Sudbury, Mass.). 2009 May-Jun:15(3):225-35. doi: 10.1097/PPO.0b013e3181a9c781. Epub [PubMed PMID: 19556909]
Palmer K, Weerasuriya S, Chandrakumaran K, Rous B, White BE, Paisey S, Srirajaskanthan R, Ramage JK. Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry. Frontiers in oncology. 2022:12():915028. doi: 10.3389/fonc.2022.915028. Epub 2022 Jul 12 [PubMed PMID: 35903705]
Level 1 (high-level) evidenceStewart RJ, Mirakhur M. Primary malignant lymphoma of the appendix. The Ulster medical journal. 1986 Oct:55(2):187-9 [PubMed PMID: 3811021]
Level 3 (low-level) evidenceRamaswamy V. Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei. Indian journal of surgical oncology. 2016 Jun:7(2):258-67. doi: 10.1007/s13193-016-0516-2. Epub 2016 Mar 19 [PubMed PMID: 27065718]
Singh MP. A general overview of mucocele of appendix. Journal of family medicine and primary care. 2020 Dec:9(12):5867-5871. doi: 10.4103/jfmpc.jfmpc_1547_20. Epub 2020 Dec 31 [PubMed PMID: 33681010]
Level 3 (low-level) evidenceHoehn RS, Rieser CJ, Choudry MH, Melnitchouk N, Hechtman J, Bahary N. Current Management of Appendiceal Neoplasms. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2021 Mar:41():1-15. doi: 10.1200/EDBK_321009. Epub [PubMed PMID: 33770459]
Tirumani SH, Fraser-Hill M, Auer R, Shabana W, Walsh C, Lee F, Ryan JG. Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review. Cancer imaging : the official publication of the International Cancer Imaging Society. 2013 Feb 22:13(1):14-25. doi: 10.1102/1470-7330.2013.0003. Epub 2013 Feb 22 [PubMed PMID: 23439060]
Ruoff C, Hanna L, Zhi W, Shahzad G, Gotlieb V, Saif MW. Cancers of the appendix: review of the literatures. ISRN oncology. 2011:2011():728579. doi: 10.5402/2011/728579. Epub 2011 Aug 11 [PubMed PMID: 22084738]
Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". The American journal of surgical pathology. 1995 Dec:19(12):1390-408 [PubMed PMID: 7503361]
Level 3 (low-level) evidencePai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Advances in anatomic pathology. 2005 Nov:12(6):291-311 [PubMed PMID: 16330927]
Level 3 (low-level) evidenceModlin IM, Kidd M, Latich I, Zikusoka MN, Eick GN, Mane SM, Camp RL. Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Annals of surgery. 2006 Jul:244(1):52-60 [PubMed PMID: 16794389]
Pham TH, Wolff B, Abraham SC, Drelichman E. Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. Annals of surgical oncology. 2006 Mar:13(3):370-6 [PubMed PMID: 16485156]
Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? The Lancet. Oncology. 2006 Jan:7(1):69-76 [PubMed PMID: 16389186]
Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. The American journal of surgical pathology. 2006 May:30(5):551-9 [PubMed PMID: 16699309]
Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C 3rd, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF. Appendiceal Mucinous Neoplasms: Diagnosis and Management. The oncologist. 2017 Sep:22(9):1107-1116. doi: 10.1634/theoncologist.2017-0081. Epub 2017 Jun 29 [PubMed PMID: 28663356]
Garg PK, Prasad D, Aggarwal S, Mohanty D, Jain BK. Acute intestinal obstruction: an unusual complication of mucocele of appendix. European review for medical and pharmacological sciences. 2011 Jan:15(1):99-102 [PubMed PMID: 21381505]
Ito H, Osteen RT, Bleday R, Zinner MJ, Ashley SW, Whang EE. Appendiceal adenocarcinoma: long-term outcomes after surgical therapy. Diseases of the colon and rectum. 2004 Apr:47(4):474-80 [PubMed PMID: 14978617]
Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Seminars in diagnostic pathology. 2004 May:21(2):134-50 [PubMed PMID: 15807473]
Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2017 Aug:33(5):511-519. doi: 10.1080/02656736.2017.1310938. Epub [PubMed PMID: 28540829]
Carr NJ, Sobin LH. Neuroendocrine tumors of the appendix. Seminars in diagnostic pathology. 2004 May:21(2):108-19 [PubMed PMID: 15807471]
Caspi B, Cassif E, Auslender R, Herman A, Hagay Z, Appelman Z. The onion skin sign: a specific sonographic marker of appendiceal mucocele. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2004 Jan:23(1):117-21; quiz 122-3 [PubMed PMID: 14756359]
Dachman AH, Lichtenstein JE, Friedman AC. Mucocele of the appendix and pseudomyxoma peritonei. AJR. American journal of roentgenology. 1985 May:144(5):923-9 [PubMed PMID: 3885692]
Wonski S, Ranzenberger LR, Carter KR. Appendix Imaging. StatPearls. 2025 Jan:(): [PubMed PMID: 31751093]
Yantiss RK, Shia J, Klimstra DS, Hahn HP, Odze RD, Misdraji J. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. The American journal of surgical pathology. 2009 Feb:33(2):248-55. doi: 10.1097/PAS.0b013e31817ec31e. Epub [PubMed PMID: 18852679]
Pickhardt PJ, Levy AD, Rohrmann CA Jr, Kende AI. Primary neoplasms of the appendix: radiologic spectrum of disease with pathologic correlation. Radiographics : a review publication of the Radiological Society of North America, Inc. 2003 May-Jun:23(3):645-62 [PubMed PMID: 12740466]
Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. European radiology. 2025 Apr:35(4):1903-1912. doi: 10.1007/s00330-024-11095-7. Epub 2024 Oct 10 [PubMed PMID: 39387873]
Gao Y, Hu B. Colonoscopy in the diagnosis and management of appendiceal disease. World journal of gastrointestinal endoscopy. 2024 Apr 16:16(4):187-192. doi: 10.4253/wjge.v16.i4.187. Epub [PubMed PMID: 38680200]
Yousef A, Yousef M, Zeineddine MA, More A, Fanaeian M, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine FA, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally CP, Kee B, Kopetz S, Goldstein D, Strach M, Williamson A, Aziz O, Barriuso J, Uppal A, White MG, Helmink B, Fournier KF, Raghav KP, Taggart MW, Overman MJ, Shen JP. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA network open. 2024 Feb 5:7(2):e240260. doi: 10.1001/jamanetworkopen.2024.0260. Epub 2024 Feb 5 [PubMed PMID: 38416491]
Portel-Gomes GM, Grimelius L, Johansson H, Wilander E, Stridsberg M. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. The American journal of surgical pathology. 2001 Oct:25(10):1261-7 [PubMed PMID: 11688460]
Teng TZJ, Thong XR, Lau KY, Balasubramaniam S, Shelat VG. Acute appendicitis-advances and controversies. World journal of gastrointestinal surgery. 2021 Nov 27:13(11):1293-1314. doi: 10.4240/wjgs.v13.i11.1293. Epub [PubMed PMID: 34950421]
Level 3 (low-level) evidenceHoeffel C, Crema MD, Belkacem A, Azizi L, Lewin M, Arrivé L, Tubiana JM. Multi-detector row CT: spectrum of diseases involving the ileocecal area. Radiographics : a review publication of the Radiological Society of North America, Inc. 2006 Sep-Oct:26(5):1373-90 [PubMed PMID: 16973770]
Mitamura A, Tsujinaka S, Fujishima F, Sawada K, Hikage M, Miura T, Kitamura Y, Hatsuzawa Y, Nakano T, Shibata C. Appendiceal mucinous neoplasms: Optimizing treatment strategies based on clinical, histological, and molecular features. World journal of clinical oncology. 2025 Aug 24:16(8):109088. doi: 10.5306/wjco.v16.i8.109088. Epub [PubMed PMID: 40901332]
Ben Aziz M, Di Napoli R. Cytoreduction (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). StatPearls. 2025 Jan:(): [PubMed PMID: 34033325]
Mohamed A, Wu S, Hamid M, Mahipal A, Cjakrabarti S, Bajor D, Selfridge JE, Asa SL. Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines. Cancers. 2022 Dec 31:15(1):. doi: 10.3390/cancers15010295. Epub 2022 Dec 31 [PubMed PMID: 36612291]
Salama MM, O'Neill MA, Ryan ÉJ, O'Sullivan NJ, Nugent TS, Temperley HC, Mehigan BJ, Larkin JO, Gallagher D, O'Kane G, McCormick PH, Kelly ME. The Optimal Approach to Surgical Management of Goblet Cell Carcinoid of the Appendix: A Systematic Review. Diagnostics (Basel, Switzerland). 2024 Aug 14:14(16):. doi: 10.3390/diagnostics14161773. Epub 2024 Aug 14 [PubMed PMID: 39202258]
Level 1 (high-level) evidenceMadonia D, Cashin P, Graf W, Ghanipour L. Appendiceal adenocarcinoma-patterns of tumor spread and prognosis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2025 Mar:51(3):108755. doi: 10.1016/j.ejso.2024.108755. Epub 2024 Oct 10 [PubMed PMID: 39443251]
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O, UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. 2021 Feb:22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18 [PubMed PMID: 33476595]
Level 1 (high-level) evidencePastier C, De Hingh IHJT, Goéré D. New insights in the management of pseudomyxoma peritonei. Journal of surgical oncology. 2024 Nov:130(6):1316-1325. doi: 10.1002/jso.27842. Epub 2024 Aug 29 [PubMed PMID: 39206531]
Strach MC, Sutherland S, Horvath LG, Mahon K. The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions. Therapeutic advances in medical oncology. 2022:14():17588359221112478. doi: 10.1177/17588359221112478. Epub 2022 Jul 23 [PubMed PMID: 35898968]
Level 3 (low-level) evidenceStueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International journal of molecular sciences. 2019 Jun 22:20(12):. doi: 10.3390/ijms20123049. Epub 2019 Jun 22 [PubMed PMID: 31234481]
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC, RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet (London, England). 2011 Dec 10:378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25 [PubMed PMID: 22119496]
Level 1 (high-level) evidenceWeaver JMJ, Hubner RA, Valle JW, McNamara MG. Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma. Cancers. 2023 Oct 11:15(20):. doi: 10.3390/cancers15204951. Epub 2023 Oct 11 [PubMed PMID: 37894318]
Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, Gui X, Isaac S, Milione M, Misdraji J, Pai RK, Rodriguez-Justo M, Sobin LH, van Velthuysen MF, Yantiss RK. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017 Dec:71(6):847-858. doi: 10.1111/his.13324. Epub 2017 Sep 19 [PubMed PMID: 28746986]
Sugarbaker PH. The natural history, gross pathology, and histopathology of appendiceal epithelial neoplasms. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2006 Aug:32(6):644-7 [PubMed PMID: 16621426]
Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000 Apr 1:88(7):1739-57 [PubMed PMID: 10738234]
Level 3 (low-level) evidenceGonzález-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. The British journal of surgery. 2004 Mar:91(3):304-11 [PubMed PMID: 14991630]
Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. Journal of surgical oncology. 2011 Jul 1:104(1):41-4. doi: 10.1002/jso.21888. Epub 2011 Feb 3 [PubMed PMID: 21294132]
Stinner B, Kisker O, Zielke A, Rothmund M. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World journal of surgery. 1996 Feb:20(2):183-8 [PubMed PMID: 8661815]
Shyu S, Choudry H, Hall L, Pingpank J, Holtzman M, Bartlett D, Pai RK. Clinicopathological analysis of appendiceal goblet cell adenocarcinoma with peritoneal metastasis: World Health Organization grade predicts survival following cytoreductive surgery with intraperitoneal chemotherapy. Histopathology. 2020 Nov:77(5):798-809. doi: 10.1111/his.14189. Epub 2020 Sep 27 [PubMed PMID: 32557796]
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Jul 10:30(20):2449-56. doi: 10.1200/JCO.2011.39.7166. Epub 2012 May 21 [PubMed PMID: 22614976]
Karande GY, Chua WM, Yiin RSZ, Wong KM, Hedgire S, Tan TJ. Spectrum of computed tomography manifestations of appendiceal neoplasms: acute appendicitis and beyond. Singapore medical journal. 2019 Apr:60(4):173-182. doi: 10.11622/smedj.2019035. Epub [PubMed PMID: 31069398]
Rault-Petit B, Do Cao C, Guyétant S, Guimbaud R, Rohmer V, Julié C, Baudin E, Goichot B, Coriat R, Tabarin A, Ramos J, Goudet P, Hervieu V, Scoazec JY, Walter T. Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE). Annals of surgery. 2019 Jul:270(1):165-171. doi: 10.1097/SLA.0000000000002736. Epub [PubMed PMID: 29557879]
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jun 20:26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Epub [PubMed PMID: 18565894]
Level 3 (low-level) evidenceMehta SS, Gelli M, Agarwal D, Goéré D. Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases. Indian journal of surgical oncology. 2016 Jun:7(2):225-9. doi: 10.1007/s13193-016-0504-6. Epub 2016 Feb 10 [PubMed PMID: 27065713]
Han CJ, Ning X, Burd CE, Spakowicz DJ, Tounkara F, Kalady MF, Noonan AM, McCabe S, Von Ah D. Chemotoxicity and Associated Risk Factors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Cancers. 2024 Jul 20:16(14):. doi: 10.3390/cancers16142597. Epub 2024 Jul 20 [PubMed PMID: 39061235]
Level 1 (high-level) evidence